6[1]Efskind PS, Bernklev T, Vatn MH, A double-blind placebo controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996. 31: 463-468
7[2]ChamiTN, Whitehead WE, BennettC, etal. Treatment of constipation-predominant irritable bowel syndrome with the opioid antagonist nalmefene glucuronide (NG) [ abstract ]. Am J Gastroenterol,1993.88:1568
8[3]Toskes PP, Connery KL. Calcium polycarbophil compared with placebo in IBS. Aliment pharmacol Ther, 1993.7:87-92
9[4]Junien JL. Riviere P. The hypersensitive gut peripheral kappa agnoists as a new pharmacological approach. Aliment pharmacol Ther , 1995.9:117-126
10[5]Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisertron. 5-HT3 receptor antagonist in patients with irritable bowel syndrome. Aliment pharmacol Ther, 1993. 175-180
4Camillert M.Management of irritable bowel syndrome[J].Grastroenterology,2001,120 (3):652-668
5Pimenintel M,Eyely J,Chow BA,et al.Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome[J].The Am J Gratroenterol,2000,95:3503-3506
